KYNTRA BIO, INC.

For the period ended Dec 31, 2025. Filed Mar 16, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 16, 2026

KYNB$3.90+4.6%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Signatures

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Annual Report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Francisco, State of California.

	KYNTRA BIO, INC.
Date: March 16, 2026	By:	/s/ Thane Wettig
		Thane WettigChief Executive Officer(Principal Executive Officer)
Date: March 16, 2026	By:	/s/ David DeLucia
		David DeLuciaSenior Vice President and Chief Financial Officer(Principal Financial and Accounting Officer)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.